Sanofi Pasteur's Toronto Site, Canada

Total Page：16

File Type：pdf, Size：1020Kb

FACT SHEET SANOFI PASTEUR’S TORONTO SITE, CANADA PUTTING ONTARIO AT THE HEART OF GLOBAL VACCINE INNOVATION SANOFI PASTEUR IN BRIEF • Sanofi Pasteur, the vaccines division of Sanofi, is a global company that provides more than one billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. • Sanofi Pasteur’s global head office is located in Lyon, France. • Sanofi Pasteur’s Canadian Headquarters is located at: 1755 Steeles Avenue West, Toronto, Ontario A CENTURY OF INNOVATION • Founded in 1914, Sanofi Pasteur Canada is among the country’s largest vaccine companies, with a proud legacy of innovations in public health. • We research, develop, manufacture and distribute life-saving vaccines for the Canadian, U.S. and international markets. PROVIDING VACCINES TO MEET GLOBAL PUBLIC HEALTH NEEDS • Our Toronto site manufactures nine products to help protect people against infectious diseases such as pertussis, diphtheria and tetanus. These products include: ® ® ® ® ® ® o Pentacel , Pediacel , Adacel , Adacel -Polio, Quadracel , Daptacel , Td Adsorbed, Td Polio Adsorbed, and Tubersol® • At the site we produce the five-component-pertussis (5cP) antigen, which helps to protect children and adults against whooping cough. • The site is home to our North American “Centre of Excellence” for bioprocess and analytical R&D – a $100 million R&D facility opened in 2011, putting Ontario at the heart of global vaccine innovation. A HISTORIC CAMPUS • Sanofi Pasteur Canada was founded in 1914 as the “Antitoxin Laboratory” within the University of Toronto and expanded facilities opened on a sprawling North Toronto farm property in 1917. • Throughout a number of mergers, acquisitions and name changes, we have partnered with public health authorities, governments, and academia. • Significant public health contributions include the pioneering development of antitoxins, insulin, heparin, polio vaccines, combination vaccines, and more. • Today, the site’s 54 acres serves as office space, R&D labs, vaccine-manufacturing facilities and heritage sites, and is home to over 1,400 employees in Industrial operations, R&D, Commercial operations, and various support functions. 1/1 .

Copy Link

Recommended publications

PEDIARIX Is a Vaccine
HIGHLIGHTS OF PRESCRIBING INFORMATION • If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior These highlights do not include all the information needed to use vaccine containing tetanus toxoid, the decision to give PEDIARIX should PEDIARIX safely and effectively. See full prescribing information for be based on potential benefits and risks. (5.2) PEDIARIX. • The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.3) PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis • Syncope (fainting) can occur in association with administration of Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus injectable vaccines, including PEDIARIX. Procedures should be in place Vaccine], Suspension for Intramuscular Injection to avoid falling injury and to restore cerebral perfusion following Initial U.S. Approval: 2002 syncope. (5.4) • If temperature ≥105°F, collapse or shock-like state, or persistent, ----------------------------- INDICATIONS AND USAGE ---------------------------- PEDIARIX is a vaccine indicated for active immunization against diphtheria, inconsolable crying lasting ≥3 hours have occurred within 48 hours after tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, receipt of a pertussis-containing vaccine, or if seizures have occurred and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants within 3 days after receipt of a pertussis-containing vaccine, the decision born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX to give PEDIARIX should be based on potential benefits and risks. (5.5) may be given as early as 6 weeks of age through 6 years of age (prior to the • For children at higher risk for seizures, an antipyretic may be 7th birthday).
[Show full text]
Peel Geographies
Peel Geographies Census Metropolitan Area (CMA) Census Division (CD) Census Subdivision (CSD) Census Metroplitan Areas consist of large Census divisions are the general term for provin- Census Subdivision is the general term for urbanized areas that surround an urban core. cially legislated areas (such as county and regional municipalities or their equivalents (such as Indian The urban core must have a population greater district) or their equivalents. Census divisions are Reserves). than 100,000. Peel is a part of the intermediate geographic areas between the Toronto Metropolitan Area. province/territory level and BROCK the municipality Count in Peel: Count: GGEORGINAEORGINA (census subdivision). 3 EEASTAST Bradford SCUGOG 1 GGWILLIMBURYWILLIMBURY UUXBRIDGEXBRIDGE Count in Peel: New Example: West NEWMARKET DURHAM Example: Mono WWHITCHURCHHITCHURCH - SSTOUFFVILLETOUFFVILLE 1 Tecumseth AURORA CCLARINGTONLARINGTON Caledon, Brampton KING Gwillimbury YORK PPICKERINGICKERING OOSHAWASHAWA Toronto RRICHMONDICHMOND HHILLILL Example: or Caledon MARKHAM WHITBY CALEDON AJAX Last Update: VVAUGHANAUGHAN Peel Region PEEL Last Update: TTORONTOORONTO 2016 BBRAMPTONRAMPTON Last Update: 2016 HHALTONALTON HHILLSILLS MMISSISSAUGAISSISSAUGA 2016 HALTONHALTON MMILTONILTON OAKVILLE BBURLINGTONURLINGTON Census Tracts (CT) Dissemination Areas (DA) Dissemination Blocks Census Tracts are small, relatively stable Dissemination areas are small, relatively stable Dissemination blocks are areas bounded on all geographic areas in census metropolitan areas geographic
[Show full text]
The Department of Arts, Culture and Media at the University of Toronto
The Department of Arts, Culture and Media at the University of Toronto Scarborough (UTSC) invites applications for a full-time teaching stream position in the area of Critical Digital Methods and Practices. The appointment will be at the rank of Assistant Professor, Teaching Stream with an expected start date of July 1, 2021, or shortly thereafter. Applicants must have earned a PhD degree in Media Studies or a related area by the time of appointment, or shortly thereafter with a demonstrated record of excellence in teaching. The successful candidate must have a breadth of experience teaching digital design, digital methods, and/or emergent techno-cultural practice. Candidates’ practice may be interdisciplinary, and must demonstrate expertise in one or more of the following areas: critical software studies, critical code studies, critical data studies; platform studies; and/or digital media practices among minoritized communities. Priority will be given to candidates who are proficient in and have demonstrated teaching experience in both applied and critical engagements with digital methods, preferably with expertise in data visualization, data retrieval, and other digital tools. Candidates must have teaching expertise in a degree granting program, including lecture preparation and delivery, curriculum development, and development of online material/lectures. Additionally, candidates must possess a demonstrated commitment to excellent pedagogical practices and demonstrated interest in teaching-related scholarly activities. Candidates must
[Show full text]
Press Release Sanofi Pasteur Sanofi Pasteur Mounts Emergency
Press release Sanofi Pasteur Lyon, France, February 26, 2008 Sanofi Pasteur: www.sanofipasteur.com Media Relations: Tel.: + 33 4 37 37 50 38 Media Relations US: Tel.: + 1 570 839 44 46 Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America - Six Million Doses of StamarilTM vaccine shipped in record time to Brazil and Paraguay - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that six million doses of StamarilTM1 yellow fever vaccine have been shipped upon UNICEF’s request to respond to the yellow fever epidemic in Latin America. Brazil received four million doses of StamarilTM vaccine early February and an additional two million doses were shipped to Paraguay over the weekend in response to urgent requests from Health Authorities. “Sanofi Pasteur mobilized its teams to make this public health emergency a priority,” said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. “This ability to respond to an emergency in record time illustrates the company’s commitment to global health.” The yellow fever vaccine that was provided to Brazil and Paraguay is part of the UNICEF vaccine stockpile which is reserved for outbreak responses. Sanofi Pasteur is currently the only vaccine supplier to the UNICEF yellow fever vaccine stockpile. Sanofi Pasteur is the largest provider of yellow fever vaccine worldwide with 200 million doses of vaccine provided to 150 countries over the past 20 years. About yellow fever Yellow fever is a viral disease that occurs in both rural and urban areas in Africa and South America. There is no treatment for yellow fever, only prevention by immunization.
[Show full text]
August 2021 Factsheet Access to Vaccines
ACCESS TO HEALTHCARE AND PRICING ACCESS TO VACCINES GRI Standards : 416-1, 416-2 : Customer Health and Safety EXECUTIVE SUMMARY Vaccines have a great impact on public health. The World Health Organization considers immunization to be one of the most effective and cost-effective health interventions. It has eradicated smallpox, reduced the global incidence of polio by 99% to date,1 and dramatically reduced morbidity, disability and mortality due to diphtheria, tetanus, pertussis, tuberculosis and measles. Despite these important achievements, there is still a long way to go: 19.7 million children worldwide still have no access to a full cycle of basic vaccines.2 Due to lower immunization coverage in some countries, we are witnessing a resurgence of diseases that had almost disappeared, such as measles or pertussis. This affects people around the world, including in high-income countries. True to its vision of a world where no one suffers or dies from a vaccine-preventable disease, Sanofi Pasteur is committed to improve sustainable access to vaccines, with the help of key partnerships to provide effective and affordable vaccines and protection for all populations. This document presents some of our key commitments and initiatives illustrating our longstanding dedication to global access to health through prevention and vaccination. 1 WHO Factsheet on Poliomyelitis, last updated July 2019. https://www.who.int/news-room/fact-sheets/detail/poliomyelitis 2 WHO Factsheet on Immunization, last updated July 2020. https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage Access to Vaccines Factsheet 1 Published August 2021 TABLE OF CONTENTS 1.
[Show full text]
The Islands? in the Heart of Our City
“In memory of Rick Amsbury” Rick of memory “In www.toronto.ca/parks 416-397-BOAT (2628) 416-397-BOAT Toronto Island activities call call activities Island Toronto Parks & Recreation & Parks For information on all all on information For Parks & Recreation & Parks in Southern Ontario Southern in Shore Fishing Opportunities Fishing Shore Away to Some of the Finest the of Some to Away Only a Short Ferry Ride Ferry Short a Only Hi Mom: George and I had a fantastic day of fishing on the Island. I caught postcard! the biggest fish in my life! Here’s a postcard of the largemouth bass, it’s the same species I landed! • Borrow a Rod & Reel! & Rod a Borrow • get a get ISLANDS ISLANDS • Buy Bait! Buy • catch & catch Ms. R. Trout 1 Any Street Any Town, Anywhere Postal Code TORONTO • Rent a Canoe! a Rent • TORONTO your Visit the Boathouse: the Visit Record COME FISH THE FISH COME COME FISH THE FISH COME The Toronto Islands Toronto The Image Credit: Curtis Atwater Curtis Credit: Image A message from Toronto Mayor David Miller Who would be interested "As Mayor of Toronto, I am proud to invite you to in the great fishing at get involved with some fishy business happening right The Islands? in the heart of our city. In partnership with the Ontario Ministry of Natural Resources, Ontario Residents of The Islands; school Tourism, Toronto and Region Conservation Authority, groups, service clubs; people visiting and the Ontario Federation of Anglers and Hunters, Toronto for a day or two on business; we're working to get the message out about the tourists vacationing in Toronto; premier angling opportunities available on our very families on a picnic; kids, teenagers; Basic Fishing Regulations - own Toronto Islands.
[Show full text]
Expanded-Access Drugs Consentsta00011 Revised Version IRB Approved
University of North Carolina at Chapel Hill Consent to Participate in an Experimental Treatment ______________________________________________________________________________ Consent Form Version Date: April 28, 2017 IRB Protocol #: 17-1178 Title of Protocol : Expanded Access Stamaril Vaccine Principal Investigator : Margaret Vimmerstedt Principal Investigator Department : Campus Health Services Principal Investigator Phone number : 919-966-2281 Principal Investigator Email Address : [email protected] Co-Investigators: Thevy Chai, Ann Chelminski, Amy Sauls Funding Source and/or Sponsor: Sanofi Pasteur ______________________________________________________________________________ What are some general things you should know about compassionate use protocols? You are being asked to take part in an expanded access (“compassionate use”) protocol. You are invited to take part in an Expanded Access Program of Stamaril vaccine. Stamaril vaccine helps protect against yellow fever virus. This document explains why this program is being carried out. It will help you decide whether you wish to take part. Taking part in this program is completely voluntary. If anything in this document is unclear, or if you have any questions about this program, please ask one of the program team members . You may refuse or you may withdraw your consent to participate, for any reason, without penalty. You may not receive any direct benefit from receiving this treatment. There also may be risks of this therapy. Deciding not to be in the study or leaving the study before it is done will not affect your relationship with the Principal Investigator, your regular health care provider, or the University of North Carolina-Chapel Hill. You do not have to be in the protocol study in order to receive health care.
[Show full text]
Summary of Phase 3 Protocol – VAT00008
Summary of Phase 3 protocol – VAT00008 The phase 3 trial follows positive initial results from a phase 2 clinical trial (VAT00002)1. In that trial, the COVID-19 vaccine candidate was administered to 722 adults to assess the safety, reactogenicity and immunogenicity of 3 doses and to identify an optimal vaccine dose. Results showed strong rates of neutralizing antibody response with 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old), across all doses2. A 10µg antigen formulation of the SARS-CoV-2 adjuvanted recombinant protein-based vaccine developed by Sanofi Pasteur in combination with GSK’s AS03 adjuvant will be evaluated in a Phase 3 trial (VAT00008)2 for efficacy, immunogenicity and safety compared to a placebo. The trial is conducted in 2 stages, the first with a monovalent (single antigen) vaccine comprising the spike protein of the original SARS-CoV-2 virus (D614) and the second stage with bivalent (2-antigen) vaccine comprising spike protein of D614 and spike protein of the SARS-CoV-2 Beta variant (B.1.351). Participants will be categorized as naïve (not previously infected) and non-naïve (evidence of previous infection) based on serological and virological ascertainment of prior SARS-CoV-2 infection at the time of vaccination. Non-naïve participants will be capped at 20% of the total study population. The primary objective is the prevention of symptomatic COVID-19 with onset at least 14 days after the second injection of the vaccine in SARS-CoV-2 naïve individuals. Safety of the vaccines will be evaluated throughout the study compared to placebo.
[Show full text]
Toronto and Ottawa Railway 07/11/1877 Montreal Daily Witness Toronto and Ottawa Toronto
Local Railway Items from Area Papers - Toronto and Ottawa Railway 07/11/1877 Montreal Daily Witness Toronto and Ottawa Toronto. A public meeting called by the Mayor, who presided, was held in St. Andrew's Hall on Tuesday morning to discuss the proposed bonus to the Toronto and Ottawa Railway. Addresses in favor of the railway were delivered by W.H. Scott, M.P.P., President of the Company, Robert Bell, M.P.P., Ald. Canavan and others, and a resolution favoring the submission of the by-law granting the bonus of $300,000 was declared carried. 27/06/1879 Ottawa Free Press Toronto and Ottawa The Lanark County Council have refused to grant an extension of time to the Toronto and Ottawa Railroad Co. so that the bonus voted is now no longer available from that county. The people of that district will not be required to fight about the northern and southern routes for some time. 30/07/1879 Ottawa Free Press Toronto and Ottawa Meeting at city hall - scheme endorsed - full account. 03/10/1879 Ottawa Free Press Toronto and Ottawa Report of mass meeting on the Toronto and Ottawa scheme. 04/10/1879 Ottawa Citizen Toronto and Ottawa Meeting in City of Ottawa regarding by-law authorizing a bonus to the Toronto and Ottawa Railway https://news.google.ca/newspapers?nid=QBJtjoHflPwC&dat=18791004&printsec=frontpage&hl=en 11/10/1879 Montreal Daily Witness Toronto and Ottawa Perth Yesterday the Lanark County Council gave two readings to the by-law granting a bonus of $75,000 to the Toronto and Ottawa Railway on the route via Perthand ordered the same be submitted to the ratepayers on the 17th November.
[Show full text]
Most Best Top 10
Grand River in Downtown Brantford FACTS 2020 & STATS MOST BEST TOP 10 Business Friendly Micro Locations to Invest Best Cities to Buy Real City in the Americas in Canada Estate in Canada 2017/2018 FDi Report 2016 Site Selection Magazine 6h Year in a Row - 2020 Moneysense.ca 404 400 2016 population: 97,496 CANADA • LAKE HURON 10 year growth rate: 12.8% ONTARIO • 6 Kitchener- Toronto Waterloo 401 LAKE ONTARIO QEW 2 Hamilton • Industrial leases $4-$8 / net ft MICHIGAN BRANTFORD 403 Niagara Falls • Office leases $11-$18 / net ft2 Sarnia 24 Fort Erie 402 Bualo 69 London 90 75 94 • Located on Highway 403 94 401 NEW YORK • 1 hour to Toronto Detroit LAKE ERIE Erie (100 km / 60 mi) Windsor 79 275 PENNSYLVANIA • 1.5 hours to Buffalo (140 km / 85 mi) 90 Toledo U.S.A. • 2.5 hours to Detroit Pittsburgh (275 km / 170 mi) 69 Cleveland OHIO • Local workforce of over 83,000 • Nearly 1.1 million in 50 km / 30 mi 1 day trucking 100 km / 60 Serviced by • Nearly 6.0 million in 125 km / 80 mi to 160 million mi to Toronto major CN customers Int’l Airport freight lines, and 60% of all and 35 km as well as VIA • 4 local post-secondary schools manufacturers / 20 mi to passenger • Over 4,000 local students in the USA and Hamilton Int’l rail and GO 17 universities in 125 km / 80 mi Canada Airport Transit buses • • 9 colleges in 125 km / 80 mi Mitsui High-tec (Canada) Inc. We received Largest Industrial Employers considerable support from Brantford, who helped us select Company Staff Sector the site, provided us with a temporary office, Ferrero Canada Ltd./Ltée 900 Food Manufacturing and assisted us with the hiring process to staff our P&G / DHL 410 Warehouse Distribution operations here.
[Show full text]
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of Mrna Influenza Vaccine
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine June 22, 2021 -- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial -- -- Interim data anticipated by the end of 2021; outcomes from this clinical trial will inform next steps of our mRNA-based influenza vaccine program and strategy -- LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Flu seasons that are dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at-risk such as older adults and younger children. “The first clinical trial of a seasonal mRNA flu vaccine candidate is an exciting milestone in our quest for the next generation of influenza vaccines. We've all witnessed the promise of mRNA technology during this pandemic and are now looking to extend that promise to select annual vaccines,” said Jean-François Toussaint, Global Head of Research and Development, Sanofi Pasteur. “In line with our global leadership and our 70-year history of protecting people with influenza vaccines, we will always focus on developing products that demonstrate protection beyond flu, as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.
[Show full text]
Press Release INDIA
Press Release INDIA Sanofi and GSK receive approval for Phase 3 efficacy trial of their COVID-19 vaccine candidate in India Clinical trial to assess the safety, efficacy and immunogenicity of an adjuvanted recombinant-protein COVID-19 vaccine candidate Phase 3 clinical trial will include more than 35,000 volunteers from several countries, including sites in the US, Asia, Africa and Latin America Mumbai, INDIA – July 08, 2021 - Sanofi and GSK received approval for their Phase 3 clinical study in India, to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The global, randomized, double-blind Phase 3 study will include more than 35,000 volunteers aged 18 and older across sites in the US, Asia, Africa, and Latin America. As COVID-19 vaccination becomes available, study participants are encouraged to receive an approved COVID-19 vaccine during the study, if they wish to do so. As part of the study design, all participants including the control group will be offered the study vaccine as soon as it is determined to be safe and effective. “India is participating in Sanofi Pasteur’s pivotal Phase 3 study, and subject to subsequent approvals, we should soon begin enrollment of study participants in the country.” said Annapurna Das, Country Head, Sanofi Pasteur India. “As the virus continues to evolve, we are anticipating what will be needed in the coming months and years, and accordingly, have adapted our vaccine development program. We believe our COVID-19 adjuvanted, recombinant vaccine can make a significant contribution to the ongoing fight against COVID-19 and are committed to initiating our clinical program in India, at the earliest” she added About the Phase 3 study The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS- CoV-2 naïve adults, with secondary endpoints being the prevention of severe COVID-19 disease and prevention of asymptomatic infection.
[Show full text]